Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

ClinicalTrials.gov ID: NCT00673049

Public ClinicalTrials.gov record NCT00673049. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).

Study identification

NCT ID
NCT00673049
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
583 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2008 (Type not available)
Primary completion
Mar 2011 (Actual)
Completion
Apr 2012 (Actual)
Last update posted
Jul 24, 2013

2008 – 2012

United States locations

U.S. sites
69
U.S. states
23
U.S. cities
56
Facility City State ZIP Site status
Pfizer Investigational Site Fort Smith Arkansas 72903 —
Pfizer Investigational Site Hot Springs Arkansas 71913 —
Pfizer Investigational Site Lakeport California 95453 —
Pfizer Investigational Site Orange California 92868-3298 —
Pfizer Investigational Site Orange California 92868 —
Pfizer Investigational Site Petaluma California 94954 —
Pfizer Investigational Site Santa Rosa California 95403 —
Pfizer Investigational Site Thousand Oaks California 91360 —
Pfizer Investigational Site Westlake Valley California 91360 —
Pfizer Investigational Site Denver Colorado 80205 —
Pfizer Investigational Site Lafayette Colorado 80026 —
Pfizer Investigational Site Hollywood Florida 33021 —
Pfizer Investigational Site Lake City Florida 32024 —
Pfizer Investigational Site Lake City Florida 32055 —
Pfizer Investigational Site Pembroke Pines Florida 33028 —
Pfizer Investigational Site Alpharetta Georgia 30005 —
Pfizer Investigational Site Atlanta Georgia 30308 —
Pfizer Investigational Site Atlanta Georgia 30322 —
Pfizer Investigational Site Atlanta Georgia 30342 —
Pfizer Investigational Site Conyers Georgia 30094 —
Pfizer Investigational Site Cumming Georgia 30041 —
Pfizer Investigational Site Decatur Georgia 30033 —
Pfizer Investigational Site Duluth Georgia 30096 —
Pfizer Investigational Site Lake Spivey Georgia 30236 —
Pfizer Investigational Site Lawrenceville Georgia 30046 —
Pfizer Investigational Site Snellville Georgia 30078 —
Pfizer Investigational Site Bloomington Illinois 61701 —
Pfizer Investigational Site Peoria Illinois 61615 —
Pfizer Investigational Site Beech Grove Indiana 46107 —
Pfizer Investigational Site Indianapolis Indiana 46237 —
Pfizer Investigational Site Indianapolis Indiana 46260 —
Pfizer Investigational Site Cedar Rapids Iowa 52402 —
Pfizer Investigational Site Waterloo Iowa 50701 —
Pfizer Investigational Site Louisville Kentucky 40207 —
Pfizer Investigational Site Bethesda Maryland 20817 —
Pfizer Investigational Site New Albany Mississippi 38652 —
Pfizer Investigational Site Billings Montana 59102 —
Pfizer Investigational Site Butte Montana 59701 —
Pfizer Investigational Site Lebanon New Hampshire 03756 —
Pfizer Investigational Site Manchester New Hampshire 03102 —
Pfizer Investigational Site Amherst New York 14221 —
Pfizer Investigational Site Buffalo New York 14263 —
Pfizer Investigational Site Lake Success New York 11042 —
Pfizer Investigational Site Manhasset New York 11030 —
Pfizer Investigational Site New Hyde Park New York 11040 —
Pfizer Investigational Site The Bronx New York 10461 —
Pfizer Investigational Site The Bronx New York 10467 —
Pfizer Investigational Site Columbus Ohio 43210 —
Pfizer Investigational Site Columbus Ohio 43221 —
Pfizer Investigational Site Norman Oklahoma 73071 —
Pfizer Investigational Site Oklahoma City Oklahoma 73102 —
Pfizer Investigational Site Oklahoma City Oklahoma 73109 —
Pfizer Investigational Site Oklahoma City Oklahoma 73120 —
Pfizer Investigational Site Tulsa Oklahoma 74104 —
Pfizer Investigational Site Tulsa Oklahoma 74133 —
Pfizer Investigational Site Tulsa Oklahoma 74136 —
Pfizer Investigational Site Philadelphia Pennsylvania 19104 —
Pfizer Investigational Site Philadelphia Pennsylvania 19107 —
Pfizer Investigational Site Germantown Tennessee 38138 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Charlottesville Virginia 22908-0334 —
Pfizer Investigational Site Charlottesville Virginia 22908-0716 —
Pfizer Investigational Site Gloucester Virginia 23601 —
Pfizer Investigational Site Glouster Virginia 23061 —
Pfizer Investigational Site Newport News Virginia 23601 —
Pfizer Investigational Site Williamsburg Virginia 23185 —
Pfizer Investigational Site Wenatchee Washington 98801 —
Pfizer Investigational Site Wheeling West Virginia 26003-6300 —
Pfizer Investigational Site Cody Wyoming 82414 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00673049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 24, 2013 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00673049 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →